Clinical trials: Esmolol
Diabetic Foot Ulcer
Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers
The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU).
- Trial name
- NCT03998436
- Testing
- Esmolol Hydrochloride, Only Standard of Care, Vehicle Gel
- Where
- 14 sites in India
- Volunteers
- 176 people
- Sponsor
- Novalead Pharma Private Limited
Healthy
A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers
The study consists of a Pilot Phase (to assess safety and the local tolerability of highest AOP LDLA202 dose versus placebo) and a Main Treatment Phase (to compare PK, PD and safety and tolerability of AOP LDLA202, ONO LDL50 and…
- Trial name
- NCT01652898
- Testing
- LDLA202, ONO LDL50, Esmolol hydrochloride
- Where
- Czechia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AOP Orphan Pharmaceuticals AG
Diabetic Foot Ulcer
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU).
- Trial name
- NCT01113515
- Testing
- Esmolol hydrochloride
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 44 people
- Sponsor
- Novalead Pharma Private Limited
Healthy Volunteers
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
- Trial name
- NCT03347968
- Testing
- MEDI0382, Warfarin, Esmolol
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Hemorrhagic Stroke
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion.
- Trial name
- ETHICHS (NCT03743103)
- Testing
- Brevibloc, 10 Mg/mL Intravenous Solution, Nitroprusside, Sodium
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Healthy Volunteers, Pharmacokinetics/Dynamics Study
A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol
Pharmacokinetics, pharmacodynamics and tolerability of AOP200704 infusion is compared to that of Esmolol by measurement of plasma concentrations of AOP200704, esmolol and their metabolites, by assessing the effect of both drugs…
- Trial name
- NCT01313143
- Testing
- AOP200704, Esmolol hydrochloride, infusion
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AOP Orphan Pharmaceuticals AG
Healthy
Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers
The study will compare the pharmacokinetics (PK), safety and tolerability of long-term infusion of lyophilized landiolol (LDLL600) against esmolol (Brevibloc) by measurement of blood concentrations of landiolol, esmolol and their…
- Trial name
- NCT01741519
- Testing
- LDLL600, Brevibloc
- Where
- Czechia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AOP Orphan Pharmaceuticals AG